Transgene SA 2019 IR
The report highlights Transgene's progress in designing and developing therapeutic vaccines and oncolytic viruses for cancer treatment in 2019. Key achievements include advancing the myvac® and Invir.IO™ platforms, with regulatory approvals obtained to start clinical trials for the individualized vaccine TG4050. The company also delivered its first multi-armed oncolytic viruses under its collaboration with AstraZeneca. On the sustainability front, Transgene reported a workforce of 159 employees in France, with women representing 65% of the team and achieving a score of 90 out of 100 on the Professional Equality Index.
Company: Transgene SA
Sector: Health Care
Country: France
Year: 2019
Type: IR
Pages: 224
Transgene SA
Universal Registration Document
The report highlights Transgene's progress in designing and developing therapeutic vaccines and oncolytic viruses for cancer treatment in 2019. Key achievements include advancing the myvac® and Invir.IO™ platforms, with regulatory approvals obtained to start clinical trials for the individualized vaccine TG4050. The company also delivered its first multi-armed oncolytic viruses under its collaboration with AstraZeneca. On the sustainability front, Transgene reported a workforce of 159 employees in France, with women representing 65% of the team and achieving a score of 90 out of 100 on the Professional Equality Index.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Published
Apr 2, 2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Women on Board
Employees